Echosens, the leader in non-invasive liver diagnostics, has partnered with United Digestive, the largest gastroenterology platform in the Southeast, to bring FibroScan® to 11 clinics across ...

About Echosens Pioneer in its field, Echosens, significantly changed the practice of liver assessment with FibroScan ®, the non-invasive solution for comprehensive management of liver health.

Over 60% of patients who received ervogastat plus clesacostat for 48 weeks achieved MASH resolution without fibrosis worsening. The combination was associated with a worsening fasting lipid and ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Hemas Holdings PLC yesterday said it sustained a positive trajectory in the first quarter of FY2026 from the previous year, ...

Surveillance of hepatocellular carcinoma (HCC), via 6-monthly ultrasonography with alpha-fetoprotein testing, is currently ...

LYM received research funding from Gilead Sciences and Roche Diagnostics. W-KS received speaker’s fees from AstraZeneca and Echosens, is an advisory board member and received speaker’s fees of Abbott, ...

Measuring waist circumference may be an effective means of assessing MASLD risk in those not classified as having obesity ...

Liver Disease Diagnostics Market Research, 2031 Liver diseases is a general term that refers to any condition affecting the liver. These co ...